• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Theoretical issues in cost-effectiveness analysis.

作者信息

Weinstein M C, Manning W G

出版信息

J Health Econ. 1997 Feb;16(1):121-8. doi: 10.1016/s0167-6296(96)00511-5.

DOI:10.1016/s0167-6296(96)00511-5
PMID:10167343
Abstract
摘要

相似文献

1
Theoretical issues in cost-effectiveness analysis.
J Health Econ. 1997 Feb;16(1):121-8. doi: 10.1016/s0167-6296(96)00511-5.
2
Accounting for future costs in medical cost-effectiveness analysis.医疗成本效益分析中对未来成本的考量。
J Health Econ. 1997 Feb;16(1):33-64. doi: 10.1016/s0167-6296(96)00507-3.
3
Theory and methods of economic evaluation of health care.医疗保健经济评估的理论与方法。
Dev Health Econ Public Policy. 1996;4:1-245.
4
Economic foundations of cost-effectiveness analysis.成本效益分析的经济基础。
J Health Econ. 1997 Feb;16(1):1-31. doi: 10.1016/s0167-6296(96)00506-1.
5
Drawing a veil over the measurement of social welfare--a reply to Johannesson.对社会福利衡量问题的遮掩——对约翰内松的回应
J Health Econ. 1999 Jun;18(3):387-90. doi: 10.1016/s0167-6296(98)00051-4.
6
Evaluating welfare losses in the health care market.评估医疗保健市场中的福利损失。
J Health Econ. 1993 Jul;12(2):205-8. doi: 10.1016/0167-6296(93)90030-i.
7
On aggregating QALYs: a comment on Dolan.关于QALYs的汇总：对多兰的评论
J Health Econ. 1999 Jun;18(3):381-6. doi: 10.1016/s0167-6296(98)00052-6.
8
The potential to forgo social welfare gains through overrelianceon cost effectiveness/cost utility analyses in the evidence base for public health.在公共卫生证据基础中过度依赖成本效益/成本效用分析，可能会放弃社会福利收益。
J Environ Public Health. 2009;2009:107927. doi: 10.1155/2009/107927. Epub 2009 Dec 2.
9
A model is only as good as its assumptions: a reply to Peele.一个模型的好坏取决于其假设：对皮尔的回应。
J Health Econ. 1993 Jul;12(2):209-11. doi: 10.1016/0167-6296(93)90031-9.
10
The costs and effects of addressing the needs of vulnerable populations: results of 10 years of research.满足弱势群体需求的成本与效果：十年研究成果
Can J Nurs Res. 2001 Jun;33(1):65-76.

引用本文的文献

1
Preferences as fairness judgments: a critical review of normative frameworks of preference elicitation and development of an alternative based on constitutional economics.作为公平判断的偏好：对偏好诱导规范框架的批判性审视以及基于立宪经济学的替代框架的发展
Cost Eff Resour Alloc. 2024 Jan 30;22(1):10. doi: 10.1186/s12962-024-00510-x.
2
Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.纳入未来医疗成本：对癌症患者成本效益分析的影响。
Pharmacoeconomics. 2019 Jul;37(7):931-941. doi: 10.1007/s40273-019-00790-9.
3
Building Efficient Crime Prevention Strategies: Considering the Economics of Investing in Human Development.
构建高效的犯罪预防策略：考量投资于人类发展的经济学因素。
Criminol Public Policy. 2013 May;12(2):353-366. doi: 10.1111/1745-9133.12041.
4
Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?生命年所获收益中的非直接医疗成本：是否应将其纳入医疗保健干预措施的经济评估中？
Pharmacoeconomics. 2008;26(10):815-30. doi: 10.2165/00019053-200826100-00003.
5
Wickedness or folly? The ethics of NICE's decisions.邪恶还是愚蠢？英国国家卫生与临床优化研究所决策的伦理问题。
J Med Ethics. 2006 Jul;32(7):373-7; discussion 378-80. doi: 10.1136/jme.2006.016204.
6
The measurement of contingent valuation for health economics.卫生经济学中条件价值评估法的测量
Pharmacoeconomics. 2004;22(11):691-700. doi: 10.2165/00019053-200422110-00001.
7
Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.比索洛尔治疗瑞典慢性充血性心力衰竭的成本效益：使用心脏不全比索洛尔研究II试验数据进行的分析
Pharmacoeconomics. 2001;19(9):901-16. doi: 10.2165/00019053-200119090-00002.
8
Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate.赖氨酸阿司匹林对缺血事件二级预防的经济学评估。
Pharmacoeconomics. 2000 Aug;18(2):185-200. doi: 10.2165/00019053-200018020-00008.
9
Willingness to pay. What's in a name?
Pharmacoeconomics. 1998 Nov;14(5):465-70. doi: 10.2165/00019053-199814050-00001.
10
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.塞利洛尔和阿替洛尔在高血压患者心血管疾病一级预防中的健康效益及成本效益预测模型
Pharmacoeconomics. 1997 Sep;12(3):384-408. doi: 10.2165/00019053-199712030-00010.